Intellect Neurosciences and Medical Research Council Technology Announce Humanization of Next-Generation Monoclonal Antibody to Amyloid Beta With Reduced Potential for Inflammation in the Brain of Alzheimer's Patients
September 19, 2012 09:35 ET
|
Intellect Neurosciences, Inc.
NEW YORK and LONDON, Sept. 19, 2012 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying...
Intellect Neurosciences Issues Letter to Shareholders
August 07, 2012 14:50 ET
|
Intellect Neurosciences, Inc.
NEW YORK, Aug. 7, 2012 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents...
Intellect Neurosciences Adds Two New Patent Allowances to Its Global Patent Portfolio
August 01, 2012 09:35 ET
|
Intellect Neurosciences, Inc.
NEW YORK, Aug. 1, 2012 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
Intellect Neurosciences to Present at Antibody Summit in San Francisco
July 23, 2012 09:35 ET
|
Intellect Neurosciences, Inc.
NEW YORK, July 23, 2012 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCPK:ILNS) announces Dr. Daniel G. Chain, Chairman and CEO, will present at the IBC Antibody Drug Conjugates, Bispecifics...
Intellect Neurosciences in Dispute With Pharmaceutical Licensee Over $2 Million Milestone Payment
July 11, 2012 12:56 ET
|
Intellect Neurosciences, Inc.
NEW YORK, July 11, 2012 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
Intellect Neurosciences CEO to Speak at Phacilitate CNS Leaders Forum Conference
October 04, 2011 07:00 ET
|
Intellect Neurosciences, Inc.
NEW YORK, N.Y., Oct. 4, 2011 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS) a biopharmaceutical company with an internal preclinical and clinical-stage pipeline, and multiple licenses...
Intellect Neurosciences and ViroPharma Announce $126.5 Million Global Licensing Agreement to Develop and Commercialize OX1 for Friedreich's Ataxia and Other Neurodegenerative Diseases
September 30, 2011 08:14 ET
|
Intellect Neurosciences, Inc.
NEW YORK, Sept. 30, 2011 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS) announced today that Intellect has granted an exclusive License to ViroPharma Incorporated (Nasdaq:VPHM)...
Intellect Neurosciences, Inc. Obtains Notice of Allowance for Alzheimer's Beta Amyloid Vaccine from the Japan Patent Office in Relation to the Company's RECALL-VAX(TM) Technology
July 21, 2011 08:19 ET
|
Intellect Neurosciences, Inc.
NEW YORK, July 21, 2011 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc (OTCBB:ILNS), a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major...
Intellect Neurosciences, Inc. Issues Letter to Shareholders
May 24, 2011 08:43 ET
|
Intellect Neurosciences, Inc.
NEW YORK, May 24, 2011 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNSD), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...
Intellect Neurosciences CEO to Speak at International Conference on Drug Discovery for Brain Disorders in Panama City, Republic of Panama
May 18, 2011 07:00 ET
|
Intellect Neurosciences, Inc.
NEW YORK, May 18, 2011 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for...